10-K: Aprea Therapeutics Faces Going Concern, Nasdaq Delisting Risk

Aprea Therapeutics, a clinical-stage precision oncology company, reported a net loss of $12.6 million for 2025 and warned of substantial doubt about its ability to continue as a going concern, alongside a Nasdaq minimum bid price deficiency.

Summary

• Aprea Therapeutics is a clinical-stage precision medicine oncology company focused on synthetic lethality-based therapies for biomarker-defined cancers.
• The lead WEE1 inhibitor product candidate, APR-1051, is in Phase 1 dose escalation (ACESOT-1051), with the first patient enrolled in Q2 2024 and currently enrolling cohort 8 (220 mg once daily) as of March 2, 2026.
• Preliminary results for APR-1051 show early clinical proof-of-concept, including two unconfirmed partial responses (uPR) in PPP2R1A-mutated endometrial cancer patients (150 mg and 220 mg doses) with marked reductions in CA-125 levels.
• APR-1051 has demonstrated a favorable safety and tolerability profile to date, supporting a potentially improved therapeutic index.
• The second clinical-stage candidate, ATRN-119 (ATR inhibitor), completed Phase 1/2a dose escalation, determining a Recommended Phase 2 Dose (RP2D) of 1,100 mg once daily on October 15, 2025.
• Further enrollment in ATRN-119 monotherapy arms has been voluntarily paused to explore combination approaches, with preliminary signs of clinical activity including 8 stable disease cases.
• An early-stage program, APR-1602 (DYRK1A/B inhibitor), is expected to enter IND-enabling studies in Q4 2026.
• The company reported a net loss of $12.6 million for the year ended December 31, 2025, a slight improvement from $13.0 million in 2024, with an accumulated deficit of $333.6 million.
• Cash and cash equivalents stood at $14.6 million as of December 31, 2025, and the company believes this, combined with $5.6 million from a January 2026 private placement, will fund operations into Q1 2027.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the financial statement issuance date.
• Aprea Therapeutics received a Nasdaq deficiency letter on January 23, 2026, for failing to meet the minimum $1.00 bid price requirement for continued listing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative situation due to the substantial doubt about the company's ability to continue as a going concern, the Nasdaq minimum bid price deficiency, and significant accumulated losses, which overshadow the early positive clinical data for APR-1051.

Positives

• APR-1051 (WEE1 inhibitor) shows early clinical proof-of-concept with a potential dose-response trend in its Phase 1 ACESOT-1051 study.
• Two unconfirmed partial responses (uPR) were observed in PPP2R1A-mutated uterine serous carcinoma/endometrial cancer patients treated with APR-1051, including significant CA-125 reductions.
• APR-1051 has demonstrated a favorable safety and tolerability profile to date, suggesting a potentially improved therapeutic index compared to other WEE1 inhibitors.
• Preclinical data for APR-1051 supports its potential as a single agent and in rational immunotherapy combinations in HPV+ head and neck squamous cell carcinoma (HNSCC).
• ATRN-119 (ATR inhibitor) has a determined Recommended Phase 2 Dose (RP2D) of 1,100 mg once daily, indicating progress in its monotherapy development.
• ATRN-119 demonstrated a favorable tolerability profile and preliminary signs of clinical activity, including 8 stable disease cases, in biomarker-selected populations.
• Preclinical data suggests ATRN-119 has high selectivity for ATR over related PIKK kinases, potentially limiting off-target toxicity.
• Preclinical studies show ATRN-119 + olaparib combination drives tumor regression in BRCA2-deficient ovarian cancer mouse models.
• The company retains worldwide development and commercialization rights to all product candidates.
• Net loss decreased slightly from $13.0 million in 2024 to $12.6 million in 2025.
• Research and development expenses decreased by $2.3 million in 2025 compared to 2024.

Negatives

• The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future, with an accumulated deficit of $333.6 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the financial statement issuance date.
• Cash and cash equivalents of $14.6 million as of December 31, 2025, are projected to be insufficient to fund operations beyond Q1 2027, even with a recent capital raise.
• The company received a Nasdaq deficiency letter on January 23, 2026, for failing to meet the minimum $1.00 bid price requirement, risking delisting.
• Grant revenue significantly decreased from $1.5 million in 2024 to $0.3 million in 2025.
• Further enrollment in ATRN-119 monotherapy arms has been voluntarily paused, and clinical trial site activities are being wound down to explore combination approaches, which could delay monotherapy development.
• There are no ongoing clinical trials for the p53 reactivator, APR-246 (eprenetapopt), following previous Phase 3 trial failure and clinical holds.
• The company has never generated commercial revenues and may never achieve profitability.
• The company is highly dependent on the success of APR-1051 and ATRN-119, both of which are in early clinical stages.
• Reliance on a single third-party manufacturer for active pharmaceutical ingredients (APIs) for product candidates poses supply chain risks.
• The chemical structure of eprenetapopt is in the public domain, limiting composition-of-matter patent protection.

Risks

• Incurred significant losses since inception and expects to incur losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Identified conditions and events that raise substantial doubt regarding the ability to continue as a going concern.
• Requires substantial additional funding, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or elimination of research and drug development programs or future commercialization efforts.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition.
• Limited operating history makes it difficult to evaluate business success and future viability, with no commercial revenues generated to date.
• Substantial dependence on the success of APR-1051 and ATRN-119, with clinical trials potentially not being successful, leading to material harm if approval and commercialization are not achieved or are significantly delayed.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials, and initial success may not be indicative of final outcomes.
• May not be able to file INDs or IND amendments to commence additional clinical trials on expected timelines, or the FDA may not permit proceeding.
• Limited experience as a company conducting clinical trials, potentially leading to an inability to complete pivotal clinical trials.
• Difficulties in enrolling patients in clinical trials could delay or prevent necessary marketing approvals.
• Identification of serious adverse or unacceptable side effects or limited efficacy during development could lead to abandonment or limitation of product candidate development.
• Risk of expending limited resources on a particular product candidate or indication and failing to capitalize on more profitable or successful opportunities.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties to sell and market product candidates, hindering commercialization success.
• Reliance on third parties to conduct clinical trials and some aspects of research and preclinical studies, with risks of unsatisfactory performance or non-compliance.
• Inability to obtain and maintain intellectual property protection for product candidates or technology, allowing competitors to develop similar products.
• Issued patents covering product candidates could be narrowed, found invalid, or unenforceable if challenged.
• Potential claims challenging the inventorship of patents and other intellectual property.
• Never obtained marketing approval for a product candidate, and the marketing approval process is expensive, time-consuming, and uncertain.
• Failure to obtain marketing approval in foreign jurisdictions would prevent product candidates from being marketed abroad.
• FDA and other comparable regulatory authorities' policies may change, and additional government regulations could prevent, limit, or delay regulatory approval.
• Recently enacted and future legislation, and changes in existing government regulations and policies, may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and affect prices.
• Inability to obtain or maintain orphan drug exclusivity, or such exclusivity may not prevent the FDA or European Commission from approving competing products.
• Approved products may be subject to post-approval studies and ongoing regulatory requirements, with substantial penalties for non-compliance or if unanticipated problems arise.
• Product liability lawsuits could cause substantial liabilities and limit commercialization, with insurance policies potentially being inadequate.
• Governments outside of the United States may impose strict price controls, adversely affecting revenues.
• The reactivation of p53 is a novel and unproven therapeutic approach, and development of eprenetapopt may never lead to a marketable product.
• Dependence on a single third-party manufacturer for the active pharmaceutical ingredient for product candidates increases supply chain risks.
• Business and operations could suffer from IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in information security programs.
• Future success depends on the ability to retain key executive officers and attract, retain, and motivate qualified personnel.
• Expected expansion of development and regulatory capabilities, and potentially sales and marketing capabilities, may lead to difficulties in managing growth and disrupting operations.
• Employees and consultants may engage in misconduct or other improper activities, leading to significant liability and reputational harm.
• Significant deferred tax assets may become devalued if sufficient future taxable income is not generated, applicable corporate tax rates are reduced, or an ownership change occurs.
• May have taxable income as a result of the purging election made following the Holdco Reorganization.
• Foreign subsidiaries may directly become subject to U.S. federal income tax and branch profits tax, reducing after-tax returns.
• The ongoing effects of the 2017 Tax Cuts and Jobs Act (TCJA) and Global Intangible Low-Taxed Income (GILTI) could make results difficult to predict.
• Changes in U.S. federal income tax law and other jurisdictions could materially adversely affect an investment in common shares.
• Executive officers, directors, and principal stockholders may have substantial influence over matters submitted to stockholders for approval, potentially preventing new investors from influencing significant corporate decisions.
• Provisions in corporate charter documents and under Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.
• If securities analysts do not or do not continue to publish research or reports about the business, or if they publish negative evaluations, the stock price could decline.
• The price of common stock has been and may continue to be volatile and fluctuate substantially.
• Could be subject to securities class action litigation.
• As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• Continues to incur increased costs as a result of operating as a public company and becoming subject to additional laws, regulations, and listing exchange standards.
• Because no cash dividends are anticipated for the foreseeable future, capital appreciation, if any, of common stock may be investors' sole source of gain.
• Sales of a substantial number of shares of common stock by existing stockholders in the public market could cause the stock price to fall.
• The certificate of incorporation designates specific Delaware courts as the sole and exclusive forum for certain actions, which could discourage lawsuits.
• Required to meet Nasdaq continued listing requirements and other Nasdaq rules, and failure to do so may result in delisting, negatively affecting stock price and ability to raise financing.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for the foreseeable future, anticipating additional open-label safety/efficacy data for APR-1051 in Q2 2026 and completion of its dose-escalation in Q3 2026. APR-1602 is projected to enter IND-enabling studies in Q4 2026. Management believes existing cash, supplemented by a recent January 2026 private placement, will fund operations into Q1 2027, but is actively seeking additional financing. The company is strategically exploring ATRN-119 development in combination approaches with leading academic centers, including radiation in HPV+ head and neck cancer, and with I/O agents and ADCs.

Management Comments

• "We believe that precision medicine has the potential to impact patients lives in a wide range of cancer types."
• "Our approach is to inhibit these make up genes, thereby specifically killing cancer cells with defined mutations. This approach is called synthetic lethality."
• "We aspire to become a leader in this emerging field and are establishing a pipeline of clinical and preclinical programs that we believe may have broad applications to cancer treatment."
• "Preliminary results provide early clinical proof-of-concept of APR-1051."
• "Preliminary results from the ACESOT-1051 study indicate that APR-1051 has been safe and well-tolerated to date, supporting our development strategy to differentiate WEE1 inhibition through a potentially improved therapeutic index."
• "We believe ATRN-119's mechanism of action, favorable safety profile, and pharmacologic characteristics make it an ideal candidate for combination with other anti-cancer therapies."
• "We believe our programs have the potential to advance innovative treatments for cancer patients with unmet medical needs and deliver meaningful impact to patients and generate long-term value for shareholders."
• "We believe that the emerging clinical proof of concept responses, together with the potential dose-response trend that was observed with increasing single-agent activity across lower doses, and without class-limiting toxicity to date, support our development strategy of differentiated WEE1 inhibition through a potentially improved therapeutic index (TI), as low TI has been a major hurdle in the development of WEE1 inhibitors."
• "We believe that mutant p53 still has the potential to be an attractive target for novel cancer therapy due to the high incidence of p53 mutations across a range of cancer types and the universally inferior prognosis for cancer patients with mutated p53."
• "Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits."
• "Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations."
• "Management believes that our current facilities are suitable and adequate to meet our current needs. We believe that suitable additional or substitute space will be available as needed to accommodate any potential expansion of our operations."
• "We believe we are compliant in all material respects with applicable environmental laws. Presently, we do not anticipate such compliance will have a material effect on capital expenditures, earnings, or our competitive position with respect to any of our operations."
• "We consider the relationship with our employees to be good."
• "Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025... our disclosure controls and procedures were effective at the reasonable level."
• "Our management... concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report on Form 10-K."

Industry Context

StockSavvy.ai notes that Aprea Therapeutics operates in the highly competitive and rapidly advancing precision oncology sector, focusing on synthetic lethality, an emerging strategy for cancer treatment. The company's shift from mutant p53 reactivators to DNA Damage Response (DDR) pathway inhibitors aligns with broader industry trends seeking more targeted and less toxic cancer therapies. The observed clinical proof-of-concept for APR-1051 and the strategic pivot of ATRN-119 towards combination therapies reflect the industry's increasing emphasis on synergistic drug regimens to overcome resistance and expand therapeutic potential, particularly in areas like HPV+ head and neck cancer and with ADCs/immune checkpoint inhibitors. The challenges faced, such as the Nasdaq minimum bid price deficiency and the need for further funding, are common for early-stage biopharmaceutical companies navigating the capital-intensive drug development landscape.

Comparison to Industry Standards

• APR-1051 is positioned as a potential 'best-in-class WEE1 inhibitor' due to its molecular structure, high selectivity for WEE1 (IC50 of ~1.6 nM) over PLK1 (17%), PLK2 (33%), and PLK3 (12%) at high concentrations, and potential absence of QT prolongation, differentiating it from competitor WEE1 inhibitors like ZN-c3 (Azenosertib, Zentalis) and AZD-1775 (Adavosertib, Astra Zeneca) which have been associated with significant toxicities and QT prolongation.
• ATRN-119 is highlighted as the 'first oral macrocyclic ATR inhibitor to enter clinical trials,' structurally dissimilar to competitors like AZD-6738 (AstraZeneca), BAY1895344 (Bayer), and RP-3500 (Repare). It demonstrates high selectivity for ATR (IC50 of ~4 nM) over ATM (>600-fold), DNA-PK (>2000-fold), and mTOR (>2000-fold), which is presented as potentially superior to competitors (e.g., AZD-6738: 74 nM for ATR, >400x for ATM/DNA-PK, 70-310x for mTOR; BAY1895344: 36 nM for ATR, 39x for ATM/DNA-PK, 61x for mTOR; RP-3500: 0.33 nM for ATR, >20000x for ATM/DNA-PK, 30x for mTOR).
• The company's focus on synthetic lethality builds on the clinical validation seen with PARP inhibitors (e.g., Lynparza, Rubraca, Zejula, Talzenna, Pamiparib), which are the only synthetic lethality small molecule inhibitors approved to date, indicating a high-risk, high-reward strategy in an emerging field.

Corporate Governance

Legal Proceedings

• The company was not subject to any material legal proceedings during the years ended December 31, 2025 and 2024.
• To the company's knowledge, no material legal proceedings are currently pending or threatened.

Stakeholder Impact

• Shareholders face significant risk of dilution from future equity financings and potential loss of investment due to the 'going concern' warning and Nasdaq delisting risk. Capital appreciation is the sole source of gain as no dividends are anticipated.
• Employees' job security and career advancement depend on the company's ability to secure funding and successfully develop product candidates, with competition for qualified personnel being a factor.
• Future customers (patients and healthcare providers) will be impacted by the success or failure of product candidates in clinical trials, regulatory approvals, and the availability and pricing of treatments.
• Creditors face increased risk due to the company's 'going concern' warning and limited cash resources, which could affect the company's ability to meet its financial obligations.
• Suppliers and contract manufacturers are critical to the company's operations, and their performance and compliance with regulations directly impact the development and potential commercialization of product candidates.

Next Steps

• Continue to efficiently develop APR-1051, including anticipating additional open-label safety/efficacy data in Q2 2026 and expecting to complete dose-escalation in Q3 2026.
• Explore combination approaches for ATRN-119, including discussions with leading academic centers for combinations with radiation in HPV+ head and neck cancer, and investigator-led studies with I/O agents and ADCs.
• Advance APR-1602 (DYRK1A/B inhibitor) to enter IND-enabling studies in Q4 2026.
• Actively seek additional equity financing, debt financings, collaborations, strategic alliances, or licensing arrangements to support continuing operations.
• Address the Nasdaq minimum bid price deficiency to regain compliance within the 180-day grace period.
• Expand development and regulatory capabilities, and potentially sales and marketing capabilities, by hiring additional employees and improving managerial, operational, and financial systems.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt exists about our ability to continue as a going concern' and projecting cash to last only into Q1 2027. This, coupled with a Nasdaq deficiency notice for failing to meet the minimum bid price, indicates imminent and significant operational and financial risks. While there are early positive clinical signals for APR-1051, these are preliminary and do not outweigh the fundamental solvency and listing concerns. The strategic pivot for ATRN-119 also introduces uncertainty. A seasoned investor would view the combination of these factors as a strong indicator to exit the position due to high risk of capital loss and potential delisting.

Keywords

Precision Oncology, Synthetic Lethality, WEE1 Inhibitor, APR-1051, ATR Inhibitor, ATRN-119, Cancer Therapeutics, Clinical Trials, Drug Development, Biotechnology, SEC Filing, 10-K, Endometrial Cancer, Head and Neck Cancer, DNA Damage Response, Pharmaceutical, NASDAQ, Going Concern, Capital Raise, Stock Option, Restricted Stock Units